Trial Profile
A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Lymphoma; Myeloma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen
- 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
- 26 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov (NCT00508807).
- 26 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov (NCT00508807).